Pharmacogenomics: A Practical Approach for the Health Care Team (Part 2)

Sunday, October 8
8:00 AM - 5:00 PM

Pharmacogenomics (PGx), the study of how one’s genes may affect an individual’s response to medication, has reached the translational stage for various specialties in medicine. Over thirty years of research has led to promising advances in the clinical practice. This conference provides the background, resources and practical application examples to implement pharmacogenomics and make a difference in patient lives. Mayo Clinic experts, with experience leading the implementation of PGx, will provide practical guidance on a range of topics, background and research including: when to order testing, drug/gene selection, informatics, and case study working sessions.

8:00 am Welcome and Introductions

8:15 - 9:45am Pharmacogenomics: From Bench to Bedside Part II
CME (AMA PRA Category 1 Credits™) 1.5
ACPE (UAN:0853-9999-17-047-L01-P) 1.5
Attendance CEU 1.5

• Wayne (Nick) T. Nicholson, M.D., Ph.D.
• Leiwei Wang, M.D., Ph.D.

Learning Objectives:
1. Outline example institutional resources and clinical tools to assist in developing and/or implementing pharmacogenomic services.
2. Identify examples of the use of genome data-rich model systems and genome-wide techniques to gain insight into mechanisms responsible for variation in response to drug therapy.
3. Describe the major barriers to the routine implementation of pharmacogenomics across practice sites

9:45am-10am Break

10am- Noon Clinical Case Applications in Pharmacogenomics Part II
CME (AMA PRA Category 1 Credits™) 2.0
ACPE (UAN:0853-9999-17-048-L01-P) 2.0
Attendance CEU 2.0

• Fadi E. Shamoun, M.D.
• John D. Zeuli, Pharm.D., R.Ph.

Learning Objectives:
1. Define the role of pharmacogenomics testing in cardiovascular drug response.
2. Utilize genetics to minimize adverse events and maximize drug efficacy.
3. Understand the limitation of pharmacogenomics testing in practice of cardiovascular disease
4. Provide examples of how pharmacogenomic testing can be utilized prescribing medications for patients with HIV

Noon- 1pm Lunch

1:00pm- 3pm Clinical Case Applications in Pharmacogenomics Part III
CME (AMA PRA Category 1 Credits™) 2.0
ACPE (UAN:0853-9999-17-049-L01-P) 2.0
Attendance CEU 2.0

• Richard Weinshilboum, M.D.
• Wayne (Nick) T. Nicholson, M.D., Ph.D.

Learning Objectives:
1. Outline evidence‐based guidelines and literature to formulate patient‐specific medication regimen plans based on pharmacogenomic test results and other patient‐specific factors
2. Identify variants and their impact on medications for the treatment of pain.

3:00pm Break

3:15 - 5:15pm Clinical Case Applications in Pharmacogenomics Part IV
CME (AMA PRA Category 1 Credits™) 2.0
ACPE (UAN:0853-9999-17-050-L01-P) 2.0
Attendance CEU 2.0

• Christopher B. Grilli, Pharm.D., R.Ph.
• Adrijana Kekic, Pharm.D.

Learning Objectives
1. Discuss the role of CYP3A5 in guiding calcunerurin inhibitor therapy, such as tacrolimus, in solid organ transplant.
2. Review a patient case discussing necessary decision points for evaluating post-transplant pharmacogenomics.
3. Discuss potential limitations of pharmacogenomics within the transplant population.

5:15 pm Closing remarks

Wayne T. Nicholson

Assistant Professor of Anesthesiology and Pharmacology
Mayo Clinic

Wayne (Nick) Nicholson, MD, PhD, is an Assistant Professor of Anesthesiology and Pharmacology in the College of Medicine. He is a currently a Consultant on the medical staff as a Clinical Pharmacologist in the Department of Anesthesiology. In addition to licensure in both medicine and pharmacy practice, he is credentialed by the American Board of Clinical Pharmacology and the Board of Pharmaceutical Specialties.


Send Email for Wayne Nicholson

Liewei Wang

Professor of Pharmacology Co-Director Mayo Pharmacogenomics Program
Mayo Clinic

Liewei Wang, MD, received her MD degree from FuDan University, Shanghai, China, followed by a PhD. degree from the Mayo Graduate School, with an emphasis on cancer biology and cancer pharmacology. Currently, she is a Professor of the Department of Molecular Pharmacology and Experimental Therapeutics at Mayo Clinic.

Dr. Wang has developed a research program with a focus on the use of high throughput genomic technology including array based and next generation sequencing methods, joined with a cell-based model system that consists of 300 lymphoblastoid cell lines, to study mechanisms of cancer biology and antineoplastic drug resistance, both chemotherapy and radiation therapy. In addition to her career-long involvement in pharmacogenomics, she also has extensive experience in functional genomics. She is involved in many clinical translational studies which help identify and understand biomarkers associated with clinical response to endocrine therapy and chemotherapy in breast cancer patients.

Dr. Wang is a member of several key programs at Mayo including: the Mayo-NIH Comprehensive Cancer Center (MCCC) and the Mayo Center for Individualized Medicine (CIM). She is also Co-Principal Investigator and the leader of the Functional Genomics Group for the Mayo-NIH Pharmacogenetics Research Network (PGRN) and the Co-Director for the Pharmacogenomics Program in the Mayo CIM.


Send Email for Liewei Wang

Fadi Shamoun

Cardiovascular Diseases; Department of Internal Medicine; Assistant Professor of Medicine, Mayo Clinic College of Medicine
Mayo Clinic Division of Cardiovascular Diseases


Send Email for Fadi Shamoun

John Zeuli

Ambulatory Care Pharmacist - Mayo HIV Clinic;Pharmacist - Mayo Clinic Center for Tuberculosis
Mayo Clinic

John Zeuli, PharmD, BCPS, is an infectious diseases specialist pharmacist. He currently works seeing patients in the ambulatory setting in Mayo's HIV clinic, and he provides pharmacy consultation services for the Mayo Clinic Center for Tuberculosis. He completed his PGY1 pharmacotherapy residency at Mayo Clinic in 2008 and his PGY2 infectious diseases specialty pharmacy practice residency at Mayo Clinic in 2009. He worked at Mayo Clinic Hospital as a clinical pharmacist in internal medicine from 2009-2013 before taking his current position in 2013. His interests include applied pharmacogenomics, pharmacokinetics, therapeutic drug monitoring, pharmacotherapy of tuberculosis, and HIV antiretroviral therapy.


Send Email for John Zeuli

Richard Weinshilboum

Professor of Medicine and Pharmacology, Chair-Clinical Pharmacology
Mayo Clinic
Mayo Medical School-Mayo Clinic

Richard Weinshilboum, MD, joined the staff of Mayo Clinic in Rochester in 1972 after earning his M.D. degree at the University of Kansas School of Medicine. He completed residency training in internal medicine at Massachusetts General Hospital and a postdoctoral research fellowship at the National Institutes of Health in the laboratory of Nobel laureate Julius Axelrod.

He holds the academic rank of Professor of Medicine and Pharmacology at Mayo Clinic College of Medicine and he holds the Mary Lou and John H. Dasburg Professor of Cancer Genomics.

Dr. Weinshilboum is recognized as an internationally renowned medical investigator, with more than 400 peer-reviewed articles and chapters and many awards, including the Mayo Distinguished Investigator and Distinguished Educator awards.

His research has focused on pharmacogenetics and pharmacogenomics, study of the role of inheritance in individual variation in response to drugs. His research resulted in the discovery and characterization of a series of clinically important genetic polymorphisms (variations in DNA sequence involved in drug, neurotransmitter and hormone metabolism), the functional characterization of these common genetic polymorphisms, and the rapid translation of that information into clinical studies designed to test hypotheses with regard to individual variation in drug response or disease pathophysiology.

This research has also made it possible to develop molecular tests that help protect patients from life-threatening, genetically mediated adverse drug reactions.

Dr. Weinshilboum has chaired the Pharmacogenomics Research Network, a National Institutes of Health-funded initiative that includes scientists from Mayo Clinic, Harvard University and Stanford University, among others. This group of network scientists performs collaborative studies of the role of inheritance in variation in drug response.

He is past member of the advisory councils for the National Institute of General Medical Sciences and the National Human Genome Research Institute, sponsor of the Human Genome Project.


Send Email for Richard Weinshilboum

Christopher Grilli

Manager Outpatient Pharmacy
Mayo Clinic Department of Pharmacy

Christopher Grilli, Pharm.D., BCACP, of Mayo Clinic in Phoenix Arizona, is a pharmacist specializing in pharmacogenomics. Chris received his Doctorate of Pharmacy from Creighton University College of Pharmacy. In addition he is Board Certified in Ambulatory Care Pharmacy through the Board of Pharmacy Specialties. Currently he oversees outpatient pharmacy operations for Mayo Clinic Arizona. He helped found Mayo Clinic Arizona's Ambulatory Medication Therapy Management Program as well as played an integral role in bringing a pharmacogenomics program to Arizona. Chris is actively involved in researching process improvement and healthcare delivery workflows within Mayo Clinic's multidisciplinary practice. He also has overseen the formation of a full service compounding operation so that patients can have their medications individualized. In addition to his work at Mayo Clinic, Chris is a member of the policy committee for the American Pharmacist Association. As a member of this important committee Chris lends his expertise in pharmacogenomics to the largest professional pharmacist organization in the country.


Send Email for Christopher Grilli

Adrijana Kekic

Program Director of Education, Outpatient Pharmacy
Mayo Clinic Department of Pharmacy

Adrijana Kekic, Pharm D, is a Program Director of Education, Outpatient Pharmacy at Mayo Clinic in Phoenix, Arizona. She is active in clinical care, research and lecturing and has been involved in development of pharmacogenomics services and education. She is a licensed pharmacist in Arizona.
Dr. Kekic earned the Doctor of Pharmacy degree from Midwestern University College of Pharmacy in Glendale, Arizona. She is board certified ambulatory care pharmacist through Board Pharmacy Specialties (BPS) and a member of BPS Ambulatory Care Committee. She holds a certification in Pharmacogenomics from University of Florida College of Pharmacy and is pursuing a Genomic Medicine certification from Stanford University.
Adrijana has served as an adjunct faculty at Midwestern University College of Pharmacy and an instructor, preceptor and residency preceptor at Mayo School of Medical Science. She is involved with several pharmacogenomics research projects and studies in palliative care, transplant care, anesthesia and cardiology. She sits on Pharmacogenomics Task Force at Mayo Clinic.
With two decades of clinical experience and expertise in medication therapy management , Adrijana continues to advance pharmacy practice and pharmacy leadership. She is a founder of a networking platform dedicated to high impact professional women in healthcare. She lives in Arizona with her husband and son, where they enjoy hiking. Besides pharmacogenomics, her interest include languages, history, visual arts, martial arts and healthy living.


Send Email for Adrijana Kekic


Pharmacogenomics: A Practical Approach for the Health Care Team (Part 2)

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Pharmacogenomics: A Practical Approach for the Health Care Team (Part 2)